R
Ravi Kumar Paluri
Researcher at University of Alabama at Birmingham
Publications - 60
Citations - 1268
Ravi Kumar Paluri is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Cancer & Pancreatic cancer. The author has an hindex of 9, co-authored 54 publications receiving 641 citations. Previous affiliations of Ravi Kumar Paluri include UAB Hospital & Wake Forest University.
Papers
More filters
Journal ArticleDOI
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
Jaffer A. Ajani,Thomas A. D'Amico,David J. Bentrem,Joseph Chao,Carlos U. Corvera,Prajnan Das,Crystal S. Denlinger,Peter C. Enzinger,Paul T. Fanta,Farhood Farjah,Hans Gerdes,Michael Gibson,Robert E. Glasgow,James A. Hayman,Steven N. Hochwald,Wayne L. Hofstetter,David H. Ilson,Dawn E. Jaroszewski,Kimberly L. Johung,Rajesh N. Keswani,Lawrence Kleinberg,Stephen Leong,Quan P. Ly,Kristina A. Matkowskyj,Michael McNamara,Mary F. Mulcahy,Ravi Kumar Paluri,Haeseong Park,Kyle A. Perry,Jose M. Pimiento,George A. Poultsides,Robert E. Roses,Vivian E. Strong,Georgia L. Wiesner,Christopher G. Willett,Cameron D. Wright,Nicole R. McMillian,Lenora A. Pluchino +37 more
TL;DR: This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.
Journal ArticleDOI
Advances in pancreatic cancer biomarkers.
TL;DR: Current and future biomarkers that has potential serve as critical tools for early diagnostic, predictive and prognostic indications in pancreatic cancer are reviewed.
Journal ArticleDOI
First-In-Human Phase 1 Clinical Trials - A Single-Center Experience In The Era Of Modern Oncotherapeutics
Ravi Kumar Paluri,Peng Li,Ashley M. Anderson,Lakshminarayana Nandagopal,Traci McArdle,Matthew D. Young,Franscisco Robert,Gurudatta Naik,Mansoor N. Saleh +8 more
TL;DR: The observation that number of lines of prior therapy and performance status predictive of PFS and 90DM emphasizes the need to consider phase1 trials earlier, preferably upon progression following definitive therapy, reflects the new trend in precision oncology where majority received non-cytotoxic therapeutic interventions.
Journal ArticleDOI
Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.
Guru Sonpavde,Youjin Je,Fabio A.B. Schutz,Matthew D. Galsky,Ravi Kumar Paluri,Jonathan E. Rosenberg,Joaquim Bellmunt,Toni K. Choueiri +7 more
TL;DR: A trial-level meta-analysis was conducted to determine the relative risk of venous thromboembolic events (VTEs) associated with approved vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and no difference was found based on tumor type, age and trial design.
Journal ArticleDOI
Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE).
Grant R. Williams,Kelly M. Kenzik,Mariel Parman,Mustafa Al-Obaidi,Liton Francisco,Gabrielle B. Rocque,Andrew M. McDonald,Ravi Kumar Paluri,Rudolph M. Navari,Lakshmin Nandagopal,Olumide B. Gbolahan,Crystal Young-Smith,Matthew W. Robertson,Smita Bhatia +13 more
TL;DR: Performing a GA in the routine care of older adults with GI malignancies is feasible, and GA impairments are common among this population, and a fully patient-reported GA such as the CARE may facilitate broader incorporation of GA in a routine clinic work flow.